-
1
Immune checkpoint inhibitors have improved cancer therapy, but many patients do not achieve durable benefits, necessitating new strategies.
-
2
mRNA processing, including alternative splicing and RNA modifications, connects tumor characteristics with anti-tumor immunity.
-
3
Aberrant splicing in tumor cells generates abundant neoantigens, which can be utilized for developing 'off-the-shelf' mRNA vaccines.
-
4
RNA modifications like m6A create an immunosuppressive network, affecting immune checkpoint molecules and immune cell polarization.
-
5
Combining strategies targeting mRNA processing with immune checkpoint blockade shows synergistic effects in preclinical models and trials.
